PUBLISHER: DelveInsight | PRODUCT CODE: 1226612
PUBLISHER: DelveInsight | PRODUCT CODE: 1226612
"ENTYVIO Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ENTYVIO for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the ENTYVIO for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ENTYVIO for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ENTYVIO market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.
ENTYVIO (Vedolizumab) is a gut-selective biologic developed by Takeda Pharmaceutical and marketed under the trade name ENTYVIO. It is approved in the US for the treatment of adult patients with moderately to severely active UC and Crohn's disease (CD), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist. It is a humanized monoclonal antibody designed to specifically antagonize the alpha 4 beta 7 integrin, inhibiting the binding of alpha 4 beta 7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not Vascular Cell Adhesion Molecule 1 (VCAM-1). MAdCAM-1 is preferentially expressed on the gastrointestinal tract's blood vessels, and lymph nodes. The alpha 4 beta 7 integrin is expressed on a subset of circulating white blood cells, and these cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha 4 beta 7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.
Dosage
The recommended dosage of ENTYVIO in adults with UC is 300 mg administered by intravenous infusion at 0, 2, and 6 weeks and then every 8 weeks thereafter. Therapy should be discontinued in patients who show no evidence of therapeutic benefit by Week 14.
Mechanism of action
Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4B7 integrin and blocks the interaction of α4B7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit the function of the α4B1 and αEB7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1).
The α4B7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in homing T-lymphocytes to gut lymph tissue. The interaction of the α4B7 integrin with MAdCAM-1 has been an important contributor to the chronic inflammation that is a hallmark of UC and CD.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ENTYVIO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ENTYVIO for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ENTYVIO for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions